Previous 10 | Next 10 |
Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 million Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and f...
2024-02-21 17:20:45 ET More on Guardant Health Guardant Health: Vast Market Opportunity, Challenging Valuation Guardant Health forecasts upbeat Q4, 2023 revenue guidance It's JPM time! Which medtechs are expected to issue updates this week? Seeking Alpha ...
2024-02-20 16:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 22, 2024. Company management will webcast a corresponding conference call beginning at 1:30...
2024-01-28 09:25:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’m bullish on the long-term trajectory of personalized medicine stocks. These companies specialize in tailoring a holistic approach to healthcare, with medical treatments tailored to th...
2024-01-20 10:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. With bond yields falli...
2024-01-19 12:42:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Easing financial condi...
2024-01-19 05:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-17 21:22:40 ET Summary Shares of Oxford Nanopore declined by 33% after slower than expected growth in the second half of 2023. Positive outlook on the company, but profitability not expected until 2026. Challenging market with slow adoption of new technology, but new p...
COSMOS study shows Guardant Reveal™ blood test highly predictive for disease recurrence in patients with early-stage colon cancer without need for tissue specimen Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS s...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...